Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurobiological Tech (NTII) -- Ignore unavailable to you. Want to Upgrade?

To: Dr. John M. de Castro who wrote (396)	12/3/1998 11:12:00 PM
From: Cacaito	Read Replies (1) \| Respond to of 1494

Neurontin (gabapentin)for neuropathic pain, from Parke-Davis. Check on Wednesday 12/2 Prnewswire. A competitor for Memantine. But, I think Memantine side effects profile is better. Results are not so different between Neurontin and Memantine, this disorder is recalcitrant.

To: Dr. John M. de Castro who wrote (396)	12/9/1998 8:05:00 PM
From: BRAVEHEART	Respond to of 1494

Hi Gang, Thanks John for the MERZ link. Good to see NTII is collaborating with a very credible organization with like interests ( Memantine ). I just called the company ( NTI ) today. I only touched on many of the same issues we have gone over here from time to time. I did want to better understand a couple of issues. The P-2 Memantine trial has several endpoints and nocturnal pain as a primary endpoint. I'm sure existing data from earlier NTI trials and joint data by MERZ trials with Quintiles resulted in the decision to follow the path with the greatest potential for success. I'd say given that MERZ has advanced it's Memantine trials into several P-3 trials with Quintiles does suggest that there exists a history for this course of action. I cannot see how ( Cash Rich ) Big Pharma would overlook the joint potential of several late stage clinical trials... : ) I also wanted to get a feel for the likelihood of a NTI & MERZ joint collaboration with Big Pharma. I'd have to say everyone was very upbeat generally speaking. Things do seem to be on a positive footing. While nothing is settled the two companies hope to finalize something in the next several months. I personally look forward to this collaboration. It will give NTI the credibility it has been lacking. Such a collaboration will end cash concerns and send an overdue message to the street that the market cap for this company should be well above it's current level. Again nothing new on this front. Just that things remain positive and they are closer than they were six months ago... : ) BEST WISHES Jeffrey